trial · primary record
CD19/CD20 Dual-CAR-T cells
B-cell Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 12 |
| Primary completion | 2021-09-10 |
| Primary endpoint | Percentage of participants with adverse events. |
| Registry ID | NCT04260932 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:30.098Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04260932
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.